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We determined the susceptibilities of 265 invasive iso-
lates of pneumococci obtained during 1995 to 2001 in Hong
Kong to 11 antimicrobial agents and their serotypes.
Overall, 62.6% isolates were susceptible to penicillin, 20%
were intermediately resistant, and 17.4% were resistant.
The overall prevalence of levofloxacin resistance (MIC >8
µg/mL) was 3.8% but increased to 15.2% among the peni-
cillin-resistant isolates. All levofloxacin-resistant isolates
were clonally related; had reduced susceptibility to peni-
cillin, cefotaxime, and clarithromycin; and were derived
from adults >50 years of age. Of the penicillin-nonsuscep-
tible pneumococci, 90% from children <5 years of age and
54.8% from persons of all ages were of serotypes that are
included in the 7-valent pneumococcal conjugate vaccine;
93.5% from children <5 years of age and 93% from persons
of all ages were of serotypes that are included in the 23-
valent polysaccharide vaccine. 
T
he emergence of antimicrobial resistance in
Streptococcus pneumoniae worldwide is an important
public health issue because this organism is the leading
cause of many infections, particularly community-
acquired pneumonia. In many countries, rates of resistance
for penicillin, macrolides, and tetracyclines have reached
levels of 30% to 40% or higher and are increasing. In
recent years, the emergence of fluoroquinolone resistance
is being increasingly recognized among multidrug-resist-
ant strains of S. pneumoniae. Hong Kong, Ireland, Canada,
and Spain have reported increasing rates of fluoro-
quinolone resistance among S. pneumoniae (1–3). So far,
reports on fluoroquinolone resistance in S. pneumoniae
have predominantly involved respiratory tract isolates, and
whether this type of resistance is emerging among the
invasive isolates is unknown. In this study, we evaluated
the comparative activities of five fluoroquinolones against
invasive isolates of S. pneumoniae from Hong Kong that
were collected during a period when fluoroquinolone
resistance had increased rapidly among noninvasive respi-
ratory isolates. 
Materials and Methods 
Bacterial Isolates 
Stored isolates of S. pneumoniae were obtained from the
blood and cerebrospinal fluid (CSF) of patients admitted to
five hospitals in Hong Kong during 1995 to 2001. These
five hospitals were chosen because they represent the same
sentinel network that participated in an earlier study con-
ducted by the same group (4). One hospital did not store the
isolates and thus was not included in the present study. The
following numbers of isolates were obtained from each of
the hospitals: A(140 isolates from 1995 to 2001), B (22 iso-
lates from 1996 to 2001), C (34 isolates from 1997 to
2001), D (64 isolates from 1998 to 2001), and E (5 isolates
from 2001). All are public hospitals that provide acute
patient care, including all the major specialties. Hospital A
is a university teaching hospital with a bone marrow trans-
plant unit, and the others are regional hospitals. Hospitals A
and B are located in the same region, and they together
serve a population of approximately 1.4 million. Hospitals
C, D, and E serve populations of 0.6, 1, and 0.4 million,
respectively. Thus, this network together serves approxi-
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pneumococcal case-patients with a positive blood or CSF
culture in the stated periods. All invasive isolates were test-
ed for antimicrobial susceptibility. Only one isolate from
the same patient episode of infection was included. Three
patients had two episodes of infections separated by inter-
vals of 3 months to 2 years. All isolates were subcultured
and reidentified by considering the following characteris-
tics: colony morphologic features, Gram stain results,
optochin susceptibility, and bile solubility. Isolates were
stored at –20°C until they were tested in batches. 
Antimicrobial Agents and Susceptibility Testing 
E-test strips of penicillin, amoxycillin (as amoxycillin-
clavulanate 2:1), cefotaxime, cefepime, clarithromycin,
vancomycin, ciprofloxacin, levofloxacin, sparfloxacin,
gatifloxacin, and moxifloxacin were purchased from AB
Biodisk, Solna, Sweden. E-test MICs were determined fol-
lowing the manufacturer’s instructions. All susceptibility
testing was conducted in a single laboratory at the
University of Hong Kong. Test inocula were prepared from
pneumococcal colonies grown on sheep blood agar that
had been incubated for 20 to 24 h in 5% CO2. Colonies
were suspended in 0.9% saline to obtain a suspension
equivalent to a 0.5 McFarland standard of turbidity. From
this suspension, E-tests were performed on Mueller-
Hinton agar with 5% sheep blood (BBL, Becton Dickinson
Microbiology Systems, Cockeysville, MD). The plates
were incubated at 35°C in 5% CO2 for 20 h to 24 h. MICs
falling between two marks on the E-test strip were round-
ed up to the next higher twofold dilution, as recommended
in the instructions. For all MIC determinations, the bacter-
ial inocula were validated by back titration in 10% of the
tests to ensure the desired inoculum density. Quality con-
trol strains (S. pneumoniae ATCC 49619, Staphylococcus
aureus ATCC 29213, and Escherichia coli ATCC 25922)
were included with each run. Results were interpreted
according to published breakpoints of the National
Committee for Clinical Laboratory Standards (5). The term
nonsusceptible was used to denote both intermediate and
resistant isolates. For ciprofloxacin, the criteria were sus-
ceptible, <2 µg/mL; resistant, >4 µg/mL. 
Typing of Isolates 
All isolates were serotyped by the quellung reaction
(6) with sera of various levels of reactivity from the
Statens Seruminstitut (Copenhagen, Denmark). The sub-
set of 11 isolates with resistance to ciprofloxacin was
examined further by multilocus sequence typing (MLST)
and by HinfI restriction analysis of their pbp 2b and 2x
genes (7). The well-defined Spanish clones of serotypes
23F and 6B (SP264 ATCC 700669 and GM17 ATCC
700670, respectively) and a strain representative of the
fluoroquinolone-resistant variant Hong Kong23F-1 clone
were used as controls (4). 
Polymerase Chain Reaction (PCR) 
and DNA Sequencing 
The quinolone resistance–determining regions of gyrA,
gyrB, parC, and parE were amplified by using primers
described previously (8). Nucleotide sequencing was per-
formed by the ByeDye dideoxynucleotide chain termina-
tion method (Applied Biosystems, Hong Kong). The
sequences of both strands of the amplicons were deter-
mined. 
Statistical Analysis 
Chi-square or Fisher exact test was used for statistical
analysis. A p value of <0.05 was considered significant. 
Results
Emergence of Fluoroquinolone Resistance among
Multidrug-resistant Isolates 
The number of isolates obtained from different age
groups was as follows: <2 years (n = 48); 2–5 years    (n
= 40); 6–17 years (n = 14); 18–49 years (n = 30); 50–64
(n = 27), and >65 years (n = 106). Of the isolates, 256
(96.6%) were from blood, 6 from CSF, and 3 from brain
abscess. The susceptibilities of the 265 pneumococcal iso-
lates to 11 antimicrobial agents are summarized in Table
1. The annual susceptibility rates for penicillin, clar-
ithromycin, and levofloxacin are shown in Figure 1.
Overall, 166 (62.6%) were penicillin-susceptible, 53
(20%) were penicillin-intermediate, and 46 (17.3%) were
penicillin-resistant. Rates of penicillin nonsusceptibility
(MIC >0.06 µg/mL) do not differ significantly in the five
hospitals (p = 0.1): 35.7% (50 of 140) for laboratory A,
50% (11 of 22) for laboratory B, 32.4% (11 of 34) for lab-
oratory C, 37.5% (24 of 64) for laboratory D, and 60% (3
of 5) for laboratory E.
In children (ages <12 years), the rate of penicillin non-
susceptibility was significantly higher than that in adults
(>13 years of age) (48% vs. 30.9%, respectively;
p = 0.005). In general, MICs of penicillin were identical or
within one dilution difference of that of amoxicillin. For
these two penicillins, the MIC50, MIC90, and mode MIC
values were identical. On the other hand, MICs of cefo-
taxime were generally one dilution lower than that of
cefepime. High MICs of penicillin (4 µg/mL) and cefo-
taxime (4 µg/mL) were found in 2 (0.8%) and 1 (0.4%) of
265 isolates, respectively. 
Of the 265 isolates, 97 (36.6%) were clarithromycin-
susceptible, 1 (0.4%) was clarithromycin-intermediate,
and 167 (63%) were clarithromycin-resistant. In most iso-
lates, the resistance was of a high level type. Among 168
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Table 1. MICs of 11 antimicrobial agents for  Streptococcus pneumoniae  isolates based on susceptibility to penicillin
a,b 
MIC (µg/mL)  % of isolates   Antimicrobial agent and 
penicillin susceptibility status   Range  50%  90%  Mode  S  I  R 
Penicillin                
All   0.008–4  0.032  2  0.016  62.6  20.0  17.4 
Pen-S   0.008–0.064  0.016  0.032  0.016  100  0.0  0.0 
Pen-I   0.125–1  1  1  1  0.0  100  0.0 
Pen-R   2–4  2  2.0  2  0.0  0.0  100 
Amoxicillin                
All   0.016–4  0.032  2  0.016  99.6  0.4  0.0 
Pen-S   0.016–0.125  0.016  0.032  0.016  100.0  0.0  0.0 
Pen-I   0.032–2  1  2  1  100.0  0.0  0.0 
Pen-R   0.5–4  2  2  2  97.8  2.2  0.0 
Cefotaxime                
All   0.016–4  0.032  1  0.016  97.0  2.6  0.4 
Pen-S   0.016–0.125  0.016  0.032  0.016  100.0  0.0  0.0 
Pen-I   0.032–2  1  1  1  100.0  0.0  0.0 
Pen-R   0.5–4  1  2  1  82.6  15.2  2.2 
Cefepime                
All   0.016–4  0.064  2  0.064  76.2  21.9  1.9 
Pen-S   0.016–0.25  0.064  0.125  0.064  100.0  0.0  0.0 
Pen-I   0.032–1  1  2  2  66.0  34.0  0.0 
Pen-R   1–4  2  2  2  2.2  87  10.9 
Clarithromycin                
All   0.032–256  4  256  256  36.6  0.4  63.0 
Pen-S   0.032–256  0.125  256  0.125  56.0  0.0  44.0 
Pen-I   0.064–256  256  256  256  7.5  1.9  90.6 
Pen-R   2–256  4  256  2  0.0  0.0  100.0 
Vancomycin                
All   0.25–1  0.5  0.5  0.5  100.0  0.0  0.0 
Pen-S   0.25–1  0.5  0.5  0.5  100.0  0.0  0.0 
Pen-I   0.25–1  0.5  0.5  0.5  100.0  0.0  0.0 
Pen-R   0.25–1  0.5  1  0.5  100.0  0.0  0.0 
Ciprofloxacin                
All   0.25–32  1  1  1  95.8  –  4.2 
Pen-S   0.25–4  1  1  1  99.4  –  0.6 
Pen-I   0.25–32  1  1  1  94.3  –  5.7 
Pen-R   0.5–32  1  32  1  84.8  –  15.2 
Levofloxacin                 
All   0.125–32  1  1  1  96.2  0.0  3.8 
Pen-S   0.125–2  1  1  1  100.0  0.0  0.0 
Pen-I   0.125–32  1  1  1  94.3  0.0  5.7 
Pen-R   0.5–32  1  32  1  84.8  0.0  15.2 
Sparfloxacin                 
All   0.125–32  0.25  0.5  0.5  95.8  0.8  3.2 
Pen-S   0.125–1  0.25  0.5  0.5  99.4  0.6  0.0 
Pen-I   0.125–32  0.25  0.5  0.5  94.3  0.0  5.7 
Pen-R   0.25–32  0.5  32  0.5  84.8  2.2  13.0 
Gatifloxacin               
All   0.064–16  0.25  0.25  0.25  96.2  0.8  3.0 
Pen-S   0.064–1  0.25  0.25  0.25  100.0  0.0  0.0 
Pen-I   0.125–8  0.25  0.25  0.25  94.3  1.9  3.8 
Pen-R   0.125–16  0.25  8  0.25  84.8  2.2  13.0 
Moxifloxacin               
All   0.064–8  0.125  0.25  0.125  97.0  0.8  2.3 
Pen-S   0.064–1  0.125  0.25  0.125  100.0  0.0  0.0 
Pen-I   0.064–4  0.125  0.25  0.125  96.2  1.9  1.9 
Pen-R   0.125–8  0.125  4  0.125  87.0  2.2  10.9 
aN = 265; a total of 166 isolates were penicillin -susceptible (Pen -S), 53 were penicillin -intermediate (Pen -I), and 46 were penicillin -resistant (Pen -R). 
b50% and 90%, MIC 50 and MIC 90, respectively.  clarithromycin-nonsusceptible isolates, 102 (60.7%) had
MIC >32 µg/mL, and 78 (46.4%) had MIC >256 µg/mL.
Again, clarithromycin resistance rate was higher among
children than adults (83 [83%] of 100 vs. 85 [51.5%] of
165, respectively; p < 0.001). The clarithromycin-nonsus-
ceptibility rates in penicillin-susceptible and nonsuscepti-
ble isolates were 73 (44%) of 166 and 95 (95.9%) of 99,
respectively (p < 0.001). 
Overall, 10 (3.8%) of 265 isolates were resistant to lev-
ofloxacin. The levofloxacin-resistance rate increased to
15.2% among the penicillin-resistant pneumococcal iso-
lates and was 7.5% among isolates derived from persons
>50 years of age. One penicillin-susceptible isolate (S1D3)
had a ciprofloxacin MIC of 4 µg/mL. This isolate
remained susceptible to levofloxacin. The 10 resistant iso-
lates had a levofloxacin MIC from 16 µg/mLto 32 µg/mL;
8 of these were resistant to gatifloxacin (MIC range, 4–16
µg/mL), and 6 were resistant to moxifloxacin (MIC range,
4–8 µg/mL). All levofloxacin-resistant isolates were also
either intermediately resistant or resistant to penicillin
(MIC range, 1–4 µg/mL) and clarithromycin (MIC range,
2–>256 µg/mL). All levofloxacin-resistant isolates were
from adults (one from the 50-to 64-year age group and
nine from >65-year group). Seven were nosocomial infec-
tions (having onset >2 days after admission), and three
were community-acquired infections. For the lev-
ofloxacin-susceptible isolates, the rank order of potency
(MIC50/MIC90) was as follows: moxifloxacin (0.125/0.25)
> gatifloxacin (0.25/0.25) > sparfloxacin (0.25/0.5) > lev-
ofloxacin (1/1) = ciprofloxacin (1/1). 
Serotype Distribution of Isolates and 
Resistance Patterns 
Of 265 isolates, 8 isolates could not be typed; 34 differ-
ent serotypes were identified among the remaining isolates.
The serotype distribution of the isolates according to age
group of patients and penicillin resistance is shown in
Table 2. Serotype 14 was the most common serotype
(24.5%). Four serotypes (6B, 14, 19F, and 23F) accounted
for 92.9% of all penicillin-nonsusceptble isolates and
84.5% of all clarithromycin-nonsusceptible isolates. The
capsular serotypes of the levofloxacin-resistant isolates
were 14 (n = 4), 19F (n = 2), and 23F (n = 4). Serotypes
included in 7-valent pneumococcal conjugate vaccine for-
mulations (4, 6B, 9V, 14, 18C, 19F, and 23F) comprised
90.4% and 90.6% of penicillin- and clarithromycin-non-
susceptible strains isolated from persons with age <5 years,
respectively. Coverage of the 7-valent conjugate vaccine
for all isolates from young children (<5 years of age) was
89.7% (79/88). Serotypes included in the 23-valent pneu-
mococcal polysaccharide vaccine accounted for 92.9% of
penicillin-nonsusceptible and 91.1% of clarithromycin-
nonsusceptible isolates for all ages, respectively. 
Molecular Analysis of Fluoroquinolone-resistant
Isolates 
Molecular analysis of the 11 fluoroquinolone-resistant
isolates is summarized in Table 3. Analysis by MLST
showed that a single allelic profile (4-4-2-4-4-1-1) or
sequence type (ST 81) was shared by all 10 levofloxacin-
resistant isolates. Fingerprint patterns after HinfI digestion
of the amplified pbp 2x and 2b genes are shown in the
Figure 2. One fingerprint pattern for pbp 2b was shared by
nine levofloxacin-resistant isolates. The remaining lev-
ofloxacin-resistant isolate has a pattern that differed from
the major pattern by one band. A single fingerprint pattern
for pbp 2x was shared by all 10 levofloxacin-resistant iso-
lates. Both pbp 2b and 2x fingerprint patterns among the
levofloxacin-resistant isolates were indistinguishable from
that displayed by the Spain23F-1 clone. The remaining
ciprofloxacin-resistant, levofloxacin-susceptible strain had
distinct pbp 2b and 2x fingerprint patterns. Furthermore,
the 10 isolates all had similar pattern of mutations in gyrA,
parC, and parE genes. In GyrA, all 10 isolates had a S81F
or Y substitution. In ParC, the 10 isolates had at least one
amino acid substitution, and 6 isolates had two substitu-
tions, an S79F plus K137N pair. In ParE, one isolate had
no substitution. Five isolates had one substitution (I460V),
and four had two substitutions (1460V plus D435 or
E474K pair). The remaining ciprofloxacin-resistant, lev-
ofloxacin-susceptible isolate (S1D3) had a distinct MLST
pattern and PBP 2B and 2X gene profiles. This isolate had
one substitution in each of ParC and ParE. No strains had
substitutions in GyrB. 
Discussion 
This study showed that fluoroquinolone resistance
among pneumococci that cause invasive infections is
emerging. Our finding of a 3.8% resistance rate for
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Figure 1. Susceptibility rates for 265 invasive Streptococcus pneu-
moniae in Hong Kong by year, 1995–2001.levofloxacin is among the highest ever reported in the
world and could be attributed in part to suboptimal use of
the fluoroquinolones (9). In a case-control study, we have
previously shown that chronic obstructive airway disease,
nosocomial infection, nursing home residence, and expo-
sure to lesser potent fluoroquinolones were independently
associated with fluoroquinolone-resistant Streptococcus
pneumoniae (9). Elsewhere, levofloxacin resistance among
the invasive pneumococcal isolates was still rare at <1%
(10–12). In the United States, Jorgensen et al. recently
reported that fluoroquinolone-resistant pneumococci could
be also emerging in some of the Active Bacterial Core
Surveillance Areas (ABCs). Of 538 invasive pneumococci
collected from 1998 to 2000 from California, 3.2% had
ciprofloxacin MIC of >4 µg/mL(13). In general, antimicro-
bial resistance among the pneumococci occurred more fre-
quently among respiratory tract isolates than blood isolates
(2). In our previous studies, the fluoroquinolone resistance
rate among the respiratory isolates was 5.5% and 13% in
1998 and 2000, respectively (3,4). 
Our findings show that invasive pneumococci with flu-
oroquinolone resistance in this locality were related to the
multidrug-resistant Spanish 23F clone. Three different
serotypes were identified among the 10 clonally related
levofloxacin-resistant isolates, indicating that this clone is
evolving by horizontal transfer of the capsular genes.
Elsewhere, early evidence suggested that epidemic clones
could be playing a role in dissemination of fluoro-
quinolone resistance. In an analysis of 29 fluoroquinolone-
resistant pneumococci, McGee et al. reported that 6
isolates from Ireland and 1 from France were indistin-
guishable from the Spain9V-3 clone (14). In Birmingham,
George et al. recently reported that two fluoroquinolone-
resistant variants closely related to the widely distributed
penicillin-resistant Spanish9V-3 clone were emerging (15).
Furthermore, Alou et al. report that 30% of 82 pneumococ-
ci with reduced susceptibility to ciprofloxacin from 20
hospitals in Spain belonged to two internationally spread
clones: France9V-3 and Spain23F-1 (16). The emergence of
fluoroquinolone resistance among the internationally dis-
tributed S. pneumoniae clones is of concern. The Hong
Kong experience is an example of how resistance to the
fluoroquinolones could evolve rapidly in pneumococci as
a result of clonal expansion. 
This study found a high rate of macrolide resistance
among the invasive pneumococcal isolates, as was report-
ed for noninvasive isolates (4). This circumstance is likely
related to the high local use of macrolides and the dissem-
ination of several drug-resistant clones (17). Among inva-
sive isolates, our figure was similar to that reported in
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Table 2. Distribution of pneumococcal capsular types according to age group of patient and penicillin resistance, 1995–2001 
All ages  Age <5 years 
Serotype
a  No. of isolates  Penicillin-resistant (%)  No. of isolates  Penicillin-resistant (%) 
14  65  32.3  31  25.8 
23F  46  82.6  15  80.0 
6B   26  69.2  18  72.2 
3  24  0.0  1  0.0 
19F  19  78.9  9  55.6 
18C  12  0.0  4  0.0 
9V  8  0.0  2  0.0 
4  7  0.0  0  0.0 
All others   58  12.1  8  50.0 
Total  265  37.4  88  47.7 
aMIC >0.12 µg/mL. Serotypes included in 7-valent pneumococcal conjugate vaccine formulations included 4, 6B, 9V, 14, 18C, 19F, and 23F (in italics). 
Table 3. Characteristics of 11 strains of Streptococcus pneumoniae with reduced susceptibility to ciprofloxacin 
MIC (µg/mL)
b  Mutation in QRDR of
c,d 
Strain  Y  Source  Serotype
a  MLST profile
a  CIP  LVX  GAT  MO  GyrA  ParC  ParE 
S3F7  1996  A  23F  4-4-2-4-4-1-1  32  32  2  1  S81F  K137N  E474K, I460V 
S2H9  1997  A  23F  4-4-2-4-4-1-1  32  32  4  2  S81Y  K137N  D435N, I460V 
S1B7  1999  B  23F  4-4-2-4-4-1-1  32  32  8  4  S81F  S79F, K137N  I460V 
S1B9  1999  B  23F  4-4-2-4-4-1-1  32  32  16  4  S81F  S79F, K137N  I460V 
S1D5  1999  C  19F  4-4-2-4-4-1-1  32  32  8  4  S81F  S79F, K137N  I460V 
S2D6  1999  A  14  4-4-2-4-4-1-1  32  32  8  4  S81F  S79F, K137N  I460V 
S1D2  2000  C  19F  4-4-2-4-4-1-1  32  32  8  8  S81F  S79F, K137N  – 
S1D3  2000  C  4  8-8-8-1-17-1-18  4  2  0.5  0.25  –  K137N  I460V 
S2F3  2000  A  14  4-4-2-4-4-1-1  32  32  4  2  S81F  K137N  D435N, I460V 
186G1  2001  A  23F  4-4-2-4-4-1-1  32  16  2  0.5  S81F  K137N  E474K, I460V 
216D2  2001  A  14  4-4-2-4-4-1-1  32  32  4  4  S81F  S79F, K137N  I460V 
aMLST, multilocus sequence typing. Number refers to allelle of aroE, gdh, gki, recP, spi, xpt, and ddiA genes, respectively. 
bCIP, ciprofloxacin; LVX, levofloxacin; GAT, gatifloxacin; MO, moxifloxacin.  
cNo strains had mutations in GyrB sequence. QRDR, quinolone resistance–determining region. 
dS. pneumoniae numbering. Taiwan (72%) but was higher than those reported from the
United States (20.4%), Canada (14.8%), or Germany
(15.3%) (18–21). Despite early skepticism, increasing evi-
dence shows that in vitro macrolide resistance does result
in clinical and microbiologic failures in systemic pneumo-
coccal infection (22,23). Hence, in the empirical treatment
of community-acquired pneumonia, our findings imply
that monotherapy with a macrolide is not appropriate in
this region. 
Our data show that 90% or more of the resistant pneu-
mococci that cause invasive infections in persons of all
ages belonged to serotypes that are included in the 23-
valent pneumococcal polysaccharide vaccine as well as the
7-valent conjugate vaccine. The 7-valent conjugate vac-
cine is indicated in young children and is highly effective
in preventing vaccine serotype-related invasive diseases
(24). In the United States, the 7-valent conjugate vaccine
was added to the routine schedule in 2000. According to
Whitney et al. (25), after the conjugate vaccine was intro-
duced, the rate of invasive disease caused by vaccine and
vaccine-related serotypes has markedly declined. The rate
of disease caused by strains that were not susceptible to
penicillin was 35% lower in 2001 than in 1999. The rate of
disease in adults also declined (25). From the results of tri-
als reported so far, the vaccine will likely also reduce car-
riage of vaccine types of pneumococci (26,27). Hence,
resistant pneumococci might diminish as the vaccine
becomes more widely available (25,28). The effectiveness
of the 23-valent polysaccharide vaccine has not been as
dramatic. In older adults, vaccination with the polysaccha-
ride vaccine effectively reduced the rate of bacteremia but
not that of nonbacteremic pneumonia (29). The use of the
23-valent pneumococcal vaccine in Hong Kong is low
(with estimated coverage of <10% for those >65 years).
While data on the efficacy of the 23-valent pneumococcal
vaccine are considered insufficient in patients with chron-
ic obstructive pulmonary disease (30), the benefits of vac-
cinating elderly people with the 23-valent pneumococcal
vaccine are clear (31). In view of the findings from this and
our previous study that the elderly and persons with chron-
ic obstructive pulmonary disease are at high risk of devel-
oping infection by fluoroquinolone-resistant S.
pneumoniae, we believe both patient groups in this locali-
ty should receive pneumococcal vaccine. 
In conclusion, this study reported high rates of fluoro-
quinolone resistance among multidrug-resistant strains of
pneumococci that cause invasive infections among older
adults in Hong Kong. Our experience leads us to call for a
more prudent use of fluoroquinolones in all clinical set-
tings. Since carriage of pneumococci is common, collater-
al exposure could occur anytime a person is treated with
fluoroquinolones for any infection, including skin, soft tis-
sue, or urinary tract infections. In patients with chronic
obstructive pulmonary disease, high-density colonization
of the airway is common, which could explain why these
patients are at high risk for fluoroquinolone-resistant pneu-
mococci (9). In young children, high numbers of pneumo-
cocci are frequently found in the nasopharynx. If
fluoroquinolone use is extended from adults to children,
who are frequently colonized by the antimicrobial-
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Figure 2. HinfI fingerprints of the pbp genes. A) pbp2b profiles.
Lanes 1, marker; 2, Spain23F-1 clone (SP264, ATCC 700669); 3, a
ciprofloxacin-resistant, levofloxacin-susceptible strain S1D3; 4,
Spain6B clone (GM17, ATCC 700670); lane 5–14, 10 isolates of
levofloxacin resistant pneumococci (S3F7, S2H9, S1B7, S1B9,
S1D5, S2D6, S1D2, S2F3, 186G1, and 216D2, respectively); B)
pbp2x profiles. The lanes were arranged in the same sequence as
in (A). resistant serotypes, transmission and spread of fluoro-
quinolone-resistant strains would occur rapidly in the com-
munity (32). For pneumonia, all evidence so far indicates
that infection caused by pneumococci intermediately
resistant to penicillin (MIC <1 µg/L or 2 µg/mL) should
respond well to a penicillin given in appropriate doses. In
view of this and the emergence of fluoroquinolone resist-
ance in both noninvasive and invasive isolates in this local-
ity, we believe that fluoroquinolones should not be used as
first-line treatment in community-acquired pneumonia. In
local guidelines, amoxicillin-clavulanate or the combina-
tion of amoxicillin and a new macrolide are the recom-
mended first-line drugs for empirical treatment of
community-acquired pneumonia in the outpatient setting.
As pneumococcal infections become increasing difficult to
treat, public health authorities should give priority to pneu-
mococcal vaccination of persons at high risk of acquiring
infections by the resistant pneumococci. Since substantial
changes can occur in a short period, fluoroquinolone-
resistant isolates must be monitored and tracked as part of
ongoing and routine pneumococcal surveillance. 
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